Researcher
Damya Laoui
- Keywords (Vrije Universiteit Brussel):Applied biological sciences, biotechnology
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Adaptive immunology, Bacteriology
- Disciplines (Vrije Universiteit Brussel):Inflammation, Cancer therapy, Cellular therapy
Affiliations
- FORMER_Cellular and Molecular Immunology (Research group)
Member
From1 Jan 2009 → Today - Damya Laoui Lab (Research group)
Responsible
From1 Oct 2022 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2019 → 30 Sep 2022 - Department of Bio-engineering Sciences (Department)
Member
From8 Apr 2019 → Today - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2018 → 20 Oct 2022 - Faculty of Sciences and Bioengineering Sciences (Faculty)
Member
From22 Jun 2017 → 7 Sep 2017 - Van Ginderachter Lab (Research group)
Member
From1 Jan 2017 → 30 Sep 2022 - Department of Bio-engineering Sciences (Department)
Member
From1 Jan 2012 → 30 Sep 2021 - Department of Bio-engineering Sciences (Department)
Member
From1 Oct 2008 → 30 Sep 2019
Infrastructure
1 - 1 of 1
Projects
1 - 10 of 18
- Unraveling the mechanisms underlying dendritic cell clustering within the tumor microenvironmentFrom1 Oct 2024 → TodayFunding: FWO junior postdoctoral fellowship
- 3D-CELLMAP: Unveiling complex cellular interactions in tissues through 3D super-resolution protein multiplex imagingFrom1 May 2024 → TodayFunding: FWO Medium Size Research Infrastructure
- Development of tumor-derived dendritic cell therapies to prevent ovarian cancer metastasisFrom1 Nov 2023 → TodayFunding: FWO fellowships
- Defining the cDC-cellular interactome in non-small cell lung carcinoma to unleash their full potential for cancer immunotherapiesFrom1 Nov 2023 → TodayFunding: FWO fellowships
- MATRACs: Membrane Anchoring TRAfficking ChimerasFrom1 Jan 2023 → TodayFunding: BOF - iBOF
- Towards the rational design of cancer therapies combining tumorderived dendritic cell vaccinations with regulatory TFrom1 Nov 2022 → TodayFunding: FWO fellowships
- IOF Accelerator:Integrating a multimodal approach to address current challenges in immunotherapy (INTEGRAL)From1 Oct 2022 → 31 Mar 2024Funding: IOF - technology validation in real environment
- Unleashing the full potential of cDC-based immunotherapiesFrom1 Jul 2021 → TodayFunding: University - Project driven research
- cDC2s: new players in the tumor microenvironment and cancer immunotherapyFrom1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
- Deciphering the dendritic cell compartment in ovarian cancer to assess their potential as tumor vaccines.From1 Jan 2021 → TodayFunding: FWO research project (including WEAVE projects)
Publications
1 - 10 of 64
- Peroxiredoxin-1 is an H2O2 safe-guard antioxidant and signalling enzyme in M1 macrophages(2023)
Authors: Daria Ezeriņa, Trung Nghia Vo, Ting Luo, Yvon Elkrim, Anna Escoda Suarez, Gaëtan Herinckx, Didier Vertommen, Damya Laoui, Jo Van Ginderachter, Joris Messens
- Hapten/Myristoyl Functionalized Poly(propyleneimine) Dendrimers as Potent Cell Surface Recruiters of Antibodies for Mediating Innate Immune Killing(2023)
Authors: Annemiek Uvyn, Marle Elisabeth Jacqueline Vleugels, Bas de Waal, Ahmed Emad Ibrahim Hamouda, Shikha Dhiman, Benoit Louage, Lorenzo Albertazzi, Damya Laoui, E W Meijer, Bruno G. De Geest
Pages: 1-9 - Flt3L therapy increases the abundance of Treg-promoting CCR7+ cDCs in preclinical cancer models(2023)
Authors: Emile Clappaert, Daliya Kancheva, Jan Brughmans, Ayla Debraekeleer, Pauline M R Bardet, Yvon Elkrim, Dagmar Lacroix, Maida Zivalj, Ahmed E. I. Hamouda, Jo Van Ginderachter, et al.
- Correction: Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop(2023)
Authors: Yichao Hua, Gerlanda Vella, Florian Rambow, Elizabeth Allen, Asier Antoranz Martinez, Marie Duhamel, Akira Takeda, Sirpa Jalkanen, Steffie Junius, Ann Smeets, et al.
Pages: 226-226 - Dendritic cell-based cancer immunotherapy: increasing intratumoral dendritic cell abundance and potential for vaccination(2023)
Authors: Emile Clappaert, Damya Laoui, Jo Van Ginderachter
Number of pages: 171 - Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop(2022)
Authors: Yichao Hua, Gerlanda Vella, Florian Rambow, Elizabeth Allen, Asier Antoranz Martinez, Marie Duhamel, Akira Takeda, Sirpa Jalkanen, Steffie Junius, Ann Smeets, et al.
Pages: 1600-1618.e10 - The Interface of Tumour-Associated Macrophages with Dying Cancer Cells in Immuno-Oncology(2022)
Authors: Isaure Vanmeerbeek, Jannes Govaerts, Raquel S Laureano, Jenny Sprooten, Stefan Naulaerts, Daniel M Borras, Damya Laoui, Massimiliano Mazzone, Jo Van Ginderachter, Abhishek D Garg
- Junctional adhesion molecule-A is dispensable for myeloid cell recruitment and diversification in the tumor microenvironment(2022)
Authors: Máté Kiss, Els Lebegge, Aleksandar Murgaski, Helena Van Damme, Daliya Kancheva, Jan Brughmans, Isabelle Scheyltjens, Ali Talebi, Robin Maximilian Awad, Yvon Elkrim, et al.
- Efficacy of CD40 agonists is mediated by distinct cDC subsets and subverted by suppressive macrophages(2022)
Authors: Aleksandar Murgaski, Máté Kiss, Helena Van Damme, Daliya Kancheva, Isaure Vanmeerbeerk, Jiri Keirsse, Eva Hadadi, Jan Brughmans, Sana M Arnouk, Ahmed E. I. Hamouda, et al.
Pages: 3785-3801 - Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer(2022)
Authors: Aarushi Audhut Caro, Sofie Deschoemaeker, Lize Allonsius, An Coosemans, Damya Laoui